Free Trial Information
BioCentury | Jan 30, 2020
Finance

Arch backs Vizgen’s RNA imaging platform with $14M series A

...short order.” Other life science tool companies Arch has invested in include molecular imaging company Caliper Life Sciences Inc....
Read More
BioCentury | Dec 27, 2019
Company News

Two-year-old Xyphos gains exit as Astellas scoops up CAR T switch platform

...acquired by Novartis AG (NYSE:NVS; SIX:NOVN); Sugen Inc., which Pharmacia & Upjohn Inc. bought; and Caliper...
Read More
BioCentury | Dec 1, 2016
Clinical News

Xiaflex: Ph IIa data

...from baseline in surface area and volume of the treated nodule at day 57 using caliper...
Read More
BioCentury | Jun 2, 2016
Strategy

Digital Preclinical

After flying under the radar for the last three years, Vium Inc. is coming out of the shadows with a technology it thinks will change the face of in vivo testing. By bringing high tech...
Read More
BioCentury | Jun 29, 2015
Finance

Arch's golden returns

...Arch's best multiple - 40x - came from the sale of life sciences supply company Caliper Life Sciences Inc....
Read More
BioCentury | Sep 1, 2014
Clinical News

Xiaflex: Phase II started

...>=50% decrease in lipoma surface area and change in length, surface area as measured by caliper...
Read More
BioCentury | Apr 10, 2014
Tools & Techniques

Toxic assets

...to dosing decisions. de Lille is director of technical applications for in vivo imaging at Caliper...
Read More
BioCentury | Jan 13, 2014
Clinical News

Xiaflex collagenase clostridium histolyticum: Phase II data

...primary endpoint of actively reducing the visible surface area of the lipoma as measured by caliper...
Read More
BioCentury | Jan 7, 2013
Clinical News

Cavatak: Interim Phase II data

...to baseline as assessed by CT scan or a combination of CT scan and physical caliper...
Read More
BioCentury | Jun 18, 2012
Clinical News

ATX-101: Additional Phase III data

Additional data from the double-blind, European Phase III Study 17 trial in 360 patients showed that 2 mg/cm 2 ATX-101 significantly improved mean CR-SMFRS score, a co-primary endpoint, by 0.77 points from baseline to week...
Read More
Items per page:
1 - 10 of 231
BioCentury | Jan 30, 2020
Finance

Arch backs Vizgen’s RNA imaging platform with $14M series A

...short order.” Other life science tool companies Arch has invested in include molecular imaging company Caliper Life Sciences Inc....
Read More
BioCentury | Dec 27, 2019
Company News

Two-year-old Xyphos gains exit as Astellas scoops up CAR T switch platform

...acquired by Novartis AG (NYSE:NVS; SIX:NOVN); Sugen Inc., which Pharmacia & Upjohn Inc. bought; and Caliper...
Read More
BioCentury | Dec 1, 2016
Clinical News

Xiaflex: Ph IIa data

...from baseline in surface area and volume of the treated nodule at day 57 using caliper...
Read More
BioCentury | Jun 2, 2016
Strategy

Digital Preclinical

After flying under the radar for the last three years, Vium Inc. is coming out of the shadows with a technology it thinks will change the face of in vivo testing. By bringing high tech...
Read More
BioCentury | Jun 29, 2015
Finance

Arch's golden returns

...Arch's best multiple - 40x - came from the sale of life sciences supply company Caliper Life Sciences Inc....
Read More
BioCentury | Sep 1, 2014
Clinical News

Xiaflex: Phase II started

...>=50% decrease in lipoma surface area and change in length, surface area as measured by caliper...
Read More
BioCentury | Apr 10, 2014
Tools & Techniques

Toxic assets

...to dosing decisions. de Lille is director of technical applications for in vivo imaging at Caliper...
Read More
BioCentury | Jan 13, 2014
Clinical News

Xiaflex collagenase clostridium histolyticum: Phase II data

...primary endpoint of actively reducing the visible surface area of the lipoma as measured by caliper...
Read More
BioCentury | Jan 7, 2013
Clinical News

Cavatak: Interim Phase II data

...to baseline as assessed by CT scan or a combination of CT scan and physical caliper...
Read More
BioCentury | Jun 18, 2012
Clinical News

ATX-101: Additional Phase III data

Additional data from the double-blind, European Phase III Study 17 trial in 360 patients showed that 2 mg/cm 2 ATX-101 significantly improved mean CR-SMFRS score, a co-primary endpoint, by 0.77 points from baseline to week...
Read More
Items per page:
1 - 10 of 231